Kilitch Drugs India Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
- September 15, 2026
- Posted by: Harsh Piplani
- Category: Results
Kilitch Drugs India share price Rs 190.20 on 15 September 2026, up 2.27%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 1.96 crore. Q2 FY26 base a profit of Rs 8.04 crore.
Quick Answer
The Kilitch Drugs India Q2 results date for FY27 is not confirmed, and Kilitch Drugs (India) Ltd. had not filed a board meeting intimation with the NSE or BSE as of 15 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 48.92 crore in revenue and a profit of Rs 8.04 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.
The Kilitch Drugs India Q2 results FY27 announcement is the next scheduled earnings event for Kilitch Drugs (India) Ltd., manufactures and exports pharmaceutical formulations, including injectables and ophthalmic products, to regulated and semi-regulated markets. The stock traded at Rs 190.20 on the NSE on 15 September 2026, up 2.27% from the previous close of Rs 185.97, about 13.3% below its 52-week high of Rs 219.50 and 62.2% above its 52-week low of Rs 117.25.
What makes the Kilitch Drugs India Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 48.92 crore of revenue and a profit of Rs 8.04 crore, while the most recent quarter on record, Q1 FY27, produced Rs 44.88 crore and a profit of Rs 1.96 crore. Everything below is built from those reported figures rather than from any forecast.
Click Here – Get Free Investment Predictions
When Is the Kilitch Drugs India Q2 Results FY27 Date?
The Kilitch Drugs India Q2 results date for FY27 is not confirmed. As of 15 September 2026, Kilitch Drugs (India) Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.
What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Kilitch Drugs India Q2 results date becomes public through that filing rather than through any advance announcement.
The Kilitch Drugs India Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Kilitch Drugs India.
Kilitch Drugs India Q2 Results Expectations: What the Market Is Actually Tracking
No verified analyst estimate for the Kilitch Drugs India Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Kilitch Drugs India. The Kilitch Drugs India Q2 results watchlist below is built from what the company has actually reported and disclosed.
Investors tracking Kilitch Drugs India Q2 results for the September 2026 quarter should note that revenue over the past five quarters has mostly moved in a fairly narrow band of Rs 43.14 crore to Rs 53.81 crore, except for a sharp jump to Rs 89.6 crore in the March 2026 quarter. Operating profit margin also spiked to 24.71% in that quarter, compared with a 6.55% to 11.43% range in the other four quarters, which points to a seasonal or year-end pattern typical of pharma exporters around order and tender timing rather than a new normal. The June 2026 quarter reverted sharply to Rs 44.88 crore in sales and 6.55% OPM, back in line with the Jun25-Sep25-Dec25 range, so a fair base for comparison heading into the September 2026 quarter is that earlier band rather than the March 2026 outlier.
Net profit across the five quarters has swung between Rs 1.96 crore and Rs 14.88 crore, with the Mar26 quarter again standing out on the high side and Jun26 dropping back to Rs 1.96 crore. Given this pattern, what investors will be watching for in the September 2026 quarter is whether net profit and margins settle closer to the Jun25-Sep25-Dec25 range or show further quarter-to-quarter volatility. The company currently pays no dividend, choosing instead to reinvest profits back into the business, which is not unusual for a small-cap pharmaceutical exporter but is worth keeping in mind when weighing total shareholder return.
No signs of negative net worth or other major data-quality concerns appear in the underlying figures, which is a reasonable baseline for judging the upcoming results. Because the Mar26 spike sits so far outside the surrounding quarters, any year-on-year comparison drawn against that specific quarter later in FY27 would need to be read with this base-effect caveat in mind rather than taken as a sign of a step-change in the business. For now, the more informative comparison for the September 2026 quarter is against Sep25, when sales stood at Rs 48.92 crore and OPM was 10.3%. The Kilitch Drugs India Q2 results will be the key data point to confirm whether this Sep25-level run rate has held. Investors tracking the Kilitch Drugs India Q2 results should read the print against Sep25 rather than the Mar26 spike.
Check Kilitch Drugs (India) Ltd. Live Fundamentals on the Univest Screener
Kilitch Drugs India Q2 Results Preview: The Q1 FY27 Actuals It Builds On
Kilitch Drugs (India) Ltd. reported revenue of Rs 44.88 crore in Q1 FY27, up 4.03% from Rs 43.14 crore in Q1 FY26, and a profit of Rs 1.96 crore at the net level, down 13.66% from Rs 2.27 crore in Q1 FY26. These are reported actuals, not estimates.
Sequentially, revenue was down 49.91% over the March 2026 quarter figure of Rs 89.60 crore, and net profit was down 86.83% from Rs 14.88 crore in Q4 FY26. Operating margin stood at 7.56% in Q1 FY27 against 10.3% in the September 2025 quarter, which is the comparison the Kilitch Drugs India Q2 results print will be read against.
Q2 FY26 Base: The Comparison Kilitch Drugs India Q2 Results FY27 Must Beat
Kilitch Drugs (India) Ltd. reported revenue of Rs 48.92 crore and a profit of Rs 8.04 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Kilitch Drugs India Q2 results preview.
Net profit in that base quarter was above the Rs 1.96 crore just reported for Q1 FY27, so the year-on-year comparison starts from a demanding level. Revenue of Rs 48.92 crore sits above the Rs 44.88 crore of the June 2026 quarter, which frames how much sequential movement the Kilitch Drugs India Q2 results print needs to show growth.
Kilitch Drugs India Quarterly Results Trend Over the Last Four Quarters
| Quarter | Revenue (Rs Cr) | Net Profit (Rs Cr) |
|---|---|---|
| Q2 FY26 (Sep 2025) | 48.92 | 8.04 |
| Q3 FY26 (Dec 2025) | 53.81 | 4.31 |
| Q4 FY26 (Mar 2026) | 89.60 | 14.88 |
| Q1 FY27 (Jun 2026) | 44.88 | 1.96 |
Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company’s exchange filings, and they are the only basis this Kilitch Drugs India Q2 results preview uses.
Revenue across those four quarters ranged from Rs 44.88 crore to Rs 89.60 crore, and net profit from Rs 1.96 crore to Rs 14.88 crore. That spread is the honest context for the Kilitch Drugs India Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.
Key Factors That Could Shape Kilitch Drugs India Q2 Results FY27
The Kilitch Drugs India Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Kilitch Drugs India has already reported.
Valuation and returns
Kilitch Drugs trades at a price-to-earnings ratio of about 22.09 times on the market data provided, against a book value of Rs 80 per share and a current price of Rs 190.2, implying a price-to-book ratio of roughly 2.38 times. Return on equity stands at 10.6%, a moderate level for a small-cap pharmaceutical company, while return on capital employed is somewhat higher at 13.4%. There is no dividend yield currently, meaning shareholder return depends entirely on price movement and future earnings growth rather than payouts.
Price and technical context
The stock’s 52-week range runs from Rs 117.25 to Rs 219.5, with the current price of Rs 190.2 sitting above both its 50-day moving average of Rs 180.62 and its 200-day moving average of Rs 169.54. The relative strength index reads 78.5, a level typically associated with an overbought technical condition, noted here purely as a price-momentum observation rather than a signal in either direction.
Balance sheet and payouts
The debt-to-equity ratio is a modest 0.26, indicating relatively low borrowing on the balance sheet relative to equity. The company does not currently pay a dividend, so the entire return proposition for shareholders rests on earnings growth and price appreciation rather than income. The balance sheet itself does not show elevated debt-related stress, but the seasonal swings in quarterly numbers argue for viewing any single quarter’s results in the context of the surrounding quarters rather than in isolation.
Kilitch Drugs India Q2 Results FY27: Share Price and Valuation Going Into the Print
Kilitch Drugs India share price today is Rs 190.20 on the NSE, up Rs 4.23 or 2.27% from the previous close of Rs 185.97 on 15 September 2026, ahead of the Kilitch Drugs India Q2 results announcement.
| Metric | Value (15 September 2026) |
|---|---|
| NSE Symbol | KILITCH |
| Current Market Price | Rs 190.20 |
| 52-Week High | Rs 219.50 |
| 52-Week Low | Rs 117.25 |
| Market Capitalisation | Rs 665 crore |
| PE Ratio | 22.09 |
| PB Ratio | 2.38 |
| EPS (TTM) | Rs 8.61 |
| Book Value per Share | Rs 80.00 |
| Debt to Equity | 0.26 |
| Return on Equity | 10.6% |
| 50-Day Moving Average | Rs 180.62 |
| 200-Day Moving Average | Rs 169.54 |
| RSI (14) | 78.50 |
The stock trades above both its 50-day average of Rs 180.62 and its 200-day average of Rs 169.54, with a 14-day RSI of 78.50. None of this is a view on where the shares go once the Kilitch Drugs India Q2 results are announced, and no price target is offered here.
Download the Univest iOS App or Univest Android App to track Kilitch Drugs (India) Ltd. live price and quarterly earnings updates.
What Investors Should Watch When Kilitch Drugs India Q2 Results Are Announced
Four lines carry most of the information in a company of this size, and reading them in order keeps the Kilitch Drugs India Q2 results print in proportion.
- Revenue against the Rs 48.92 crore reported in the September 2025 base quarter
- Net profit against a profit of Rs 8.04 crore in that same quarter
- Operating margin against 7.56% in Q1 FY27
- Any exceptional item, provision or one-off gain disclosed alongside the numbers
A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Kilitch Drugs India Q2 results announcement should be read together with the notes to the results rather than the headline alone.
Conclusion on Kilitch Drugs India Q2 Results FY27
The Kilitch Drugs India Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Kilitch Drugs (India) Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.
On that basis the Kilitch Drugs India Q2 results FY27 print faces a base of Rs 48.92 crore in revenue and a profit of Rs 8.04 crore, with the most recent quarter having delivered Rs 44.88 crore and a profit of Rs 1.96 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Kilitch Drugs India, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Kilitch Drugs India Q2 Results FY27
What is the Kilitch Drugs India Q2 results date for FY27?
Ans. The Kilitch Drugs India Q2 results date for FY27 is not confirmed. Kilitch Drugs (India) Ltd. had not filed a board meeting intimation with the NSE or BSE as of 15 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.
What quarter do the Kilitch Drugs India Q2 results 2026 cover?
Ans. The Kilitch Drugs India Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Kilitch Drugs (India) Ltd. reports revenue, operating profit and net profit for that period, and the Kilitch Drugs India Q2 results filing also carries the notes to the accounts.
What were the Kilitch Drugs India Q1 FY27 results?
Ans. Kilitch Drugs (India) Ltd. reported revenue of Rs 44.88 crore in Q1 FY27 and a profit of Rs 1.96 crore at the net level. Revenue was up 4.03% versus Q1 FY26 and net profit was down 13.66% from Rs 2.27 crore in Q1 FY26.
What were Kilitch Drugs India Q2 FY26 results in the September 2025 quarter?
Ans. Kilitch Drugs (India) Ltd. reported revenue of Rs 48.92 crore and a profit of Rs 8.04 crore in Q2 FY26. Operating margin was 10.3%. Those figures form the base for the Kilitch Drugs India Q2 results FY27 comparison.
What are the main Kilitch Drugs India Q2 results expectations this quarter?
Ans. No verified analyst estimate is publicly available. The Kilitch Drugs India Q2 results expectations centre on revenue against the Rs 48.92 crore base, net profit against a profit of Rs 8.04 crore, operating margin against 7.56% in Q1 FY27, and any exceptional item disclosed with the numbers.
What is Kilitch Drugs India share price today ahead of the Q2 earnings?
Ans. Kilitch Drugs India share price is Rs 190.20 on the NSE as of 15 September 2026, up 2.27% from Rs 185.97. The stock is about 13.3% below its 52-week high of Rs 219.50 and 62.2% above its 52-week low of Rs 117.25, at a market capitalisation of Rs 665 crore.
Is Kilitch Drugs India a good stock to buy before the Q2 results?
Ans. This article does not offer a buy, sell or hold recommendation on Kilitch Drugs (India) Ltd. The stock trades at a price-to-book ratio of 2.38 with a return on equity of 10.6%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.
